Search Result

Results for "

Methamphetamine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Dopamine Transporter (1) Endogenous Metabolite (3) GPR52 (1) GPR55 (2) iGluR (1) mGluR (1) Monoamine Transporter (3) nAChR (1) Parasite (1) PARP (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Neurological Disease (13)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Endogenous Metabolite PARP	Others
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-121609A

Pholedrine hydrochloride	Others	Cardiovascular Disease
Pholedrine hydrochloride, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine hydrochloride is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine hydrochloride can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine hydrochloride can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome .

HY-147428

Zolunicant MM-110; (±)-18-Methoxycoronaridine	nAChR Parasite	Infection Neurological Disease
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC₅₀ of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .

HY-B1694A

Methoxyphenamine hydrochloride NSC-65644	Adrenergic Receptor	Inflammation/Immunology Endocrinology
Methoxyphenamine hydrochloride, a non-regulated analog of Methamphetamine, is a β-adrenergic receptor agonist used as a bronchodilator .

HY-119326

N-Formylmethamphetamine	Others	Neurological Disease
N-Formylmethamphetamine is an impurity in the synthesis of methamphetamine. N-Formylmethamphetamine is also a by-product of the Nagai reaction .

HY-152171

GZ-11608	Monoamine Transporter	Neurological Disease
GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .

HY-Z0283R

Benzamide (Standard)	Endogenous Metabolite PARP	Others
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-147529

mGluR2 modulator 3	mGluR	Neurological Disease
mGluR2 modulator 3 (compound 1) is a potent mGluR2 positive allosteric modulator with an EC₅₀ value of 0.87 μM. mGluR2 modulator 3 has activity in psychosis disease models such as methamphetamine-induced hyperactivity and mescaline-induced scratching in mice .

HY-132225

SB 206553	5-HT Receptor	Inflammation/Immunology
SB 206553 is a 5-HT_2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT_2A), 7.7 nM (5-HT_2B) and 7.8 nM (5-HT_2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .

HY-121609

Pholedrine	Others	Cardiovascular Disease Neurological Disease
Pholedrine, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome .

HY-157183

HSMO9	Others	Inflammation/Immunology
HSMO9 is a (+)-methamphetamine (METH)-like hapten that can be coupled to a carrier protein. HSMO9 can be used in vaccine development .

HY-N0541

Pseudoginsenoside F11 1 Publications Verification Ginsenoside A1	Endogenous Metabolite	Others
Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

HY-107696

Ro 04-5595 hydrochloride	iGluR	Neurological Disease
Ro 04-5595 hydrochloride is a GluN2B-selective NMDA receptor antagonist (K_i: 31 nM) .

HY-107541

O-1602 2 Publications Verification	GPR55	Neurological Disease
O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .

HY-115895

Trebenzomine CI-686 free base	Others	Neurological Disease
Trebenzomine (CI-686 free base) is a centrally acting psychotropic compound. Trebenzomine has both neuroleptic and stimulant activity. Trebenzomine potentiates Methamphetamine-induced self-stimulation. Trebenzomine reduces septal hyperirritability, suppression of conditioned avoidance behavior, blocks Apomorphine (HY-12723)-induced emesis in dogs .

HY-117883

GZ-793A	Monoamine Transporter	Neurological Disease
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an K_i of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction .

HY-147395

GPR52 agonist-1	GPR52	Neurological Disease
GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC₅₀ value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .

HY-107541R

O-1602 (Standard)	GPR55	Neurological Disease
O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .

HY-120788

VMAT2-IN-4	Monoamine Transporter	Others
VMAT2-IN-4 (compound 11) is a vesicular monoamine transporter-2 (VMAT2) inhibitor. VMAT2-IN-4 inhibits [ ³H]-DTBZ binding (Ki = 560 nM). VMAT2-IN-4 inhibits [ ³H]-DA (Ki = 45 nM) from entering vesicles and being taken up by cells. VMAT2-IN-4 can be used in methamphetamine addiction research .

HY-158014

JJC8-089	Dopamine Transporter	Neurological Disease
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .

HY-118990

Lobelane hydrochloride	Others	Neurological Disease
Lobelane hydrochloride is a biologically active compound that has the activity of inhibiting vesicular monoamine transporter-2 (VMAT2). Lobelane hydrochloride has a low affinity for nicotinic acetylcholine receptors (nAChR), thereby enhancing its selectivity for VMAT2. Synthetic structural changes of lobelane hydrochloride have led to some related analogs that show mild changes in affinity for VMAT2. The most potent synthetic lobelane hydrochloride obtained after structural modification has a K(i) value of 630 nM, showing significant VMAT2 selectivity. The biological activity of lobelane hydrochloride suggests that it has the potential to be used in the development of compounds to inhibit methamphetamine abuse .

Devextinetug IXT-M200	Inhibitory Antibodies	Cancer
Devextinetug (IXT-M200) is a chimeric anti-methamphetamine, mouse-derived IgG2κ antibody .

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Pseudoginsenoside F11 1 Publications Verification Ginsenoside A1	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Other Diseases Plants Endogenous metabolite Disease Research Fields Araliaceae	Endogenous Metabolite
Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

Benzamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Pholedrine	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Others
Pholedrine, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Methamphetamine

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products